109 related articles for article (PubMed ID: 20564083)
1. A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma.
Weber JS; Samlowski WE; Gonzalez R; Ribas A; Stephenson J; O'Day S; Sato T; Dorr R; Grenier K; Hersh E
Cancer; 2010 Aug; 116(15):3683-91. PubMed ID: 20564083
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma.
Papadopoulos NE; Bedikian A; Ring S; Kim KB; Hwu WJ; Gerber DL; Homsi J; Hwu P
Am J Clin Oncol; 2009 Oct; 32(5):509-14. PubMed ID: 19506454
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of imexon in patients with advanced malignancy.
Dragovich T; Gordon M; Mendelson D; Wong L; Modiano M; Chow HH; Samulitis B; O'Day S; Grenier K; Hersh E; Dorr R
J Clin Oncol; 2007 May; 25(13):1779-84. PubMed ID: 17470869
[TBL] [Abstract][Full Text] [Related]
5. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
McDermott DF; Sosman JA; Gonzalez R; Hodi FS; Linette GP; Richards J; Jakub JW; Beeram M; Tarantolo S; Agarwala S; Frenette G; Puzanov I; Cranmer L; Lewis K; Kirkwood J; White JM; Xia C; Patel K; Hersh E
J Clin Oncol; 2008 May; 26(13):2178-85. PubMed ID: 18445842
[TBL] [Abstract][Full Text] [Related]
6. Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy.
Hwu WJ; Knight RD; Patnana M; Bassett R; Papadopoulos NE; Kim KB; Hwu P; Bedikian A
Melanoma Res; 2010 Dec; 20(6):501-6. PubMed ID: 20859231
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
Weber JS; Zarour H; Redman B; Trefzer U; O'Day S; van den Eertwegh AJ; Marshall E; Wagner S
Cancer; 2009 Sep; 115(17):3944-54. PubMed ID: 19536884
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.
Gollob JA; Veenstra KG; Parker RA; Mier JW; McDermott DF; Clancy D; Tutin L; Koon H; Atkins MB
J Clin Oncol; 2003 Jul; 21(13):2564-73. PubMed ID: 12829677
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
Lissoni P; Vaghi M; Ardizzoia A; Malugani F; Fumagalli E; Bordin V; Fumagalli L; Bordoni A; Mengo S; Gardani GS; Tancini G
In Vivo; 2002; 16(2):93-6. PubMed ID: 12073777
[TBL] [Abstract][Full Text] [Related]
11. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma.
Hersh EM; O'Day SJ; Ribas A; Samlowski WE; Gordon MS; Shechter DE; Clawson AA; Gonzalez R
Cancer; 2010 Jan; 116(1):155-63. PubMed ID: 19877111
[TBL] [Abstract][Full Text] [Related]
12. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
Bedikian AY; Millward M; Pehamberger H; Conry R; Gore M; Trefzer U; Pavlick AC; DeConti R; Hersh EM; Hersey P; Kirkwood JM; Haluska FG;
J Clin Oncol; 2006 Oct; 24(29):4738-45. PubMed ID: 16966688
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
Gibbs P; Anderson C; Pearlman N; LaClaire S; Becker M; Gatlin K; O'Driscoll M; Stephens J; Gonzalez R
Cancer; 2002 Jan; 94(2):470-6. PubMed ID: 11900232
[TBL] [Abstract][Full Text] [Related]
14. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
O'Day SJ; Atkins MB; Boasberg P; Wang HJ; Thompson JA; Anderson CM; Gonzalez R; Lutzky J; Amatruda T; Hersh EM; Weber JS
J Clin Oncol; 2009 Dec; 27(36):6207-12. PubMed ID: 19917850
[TBL] [Abstract][Full Text] [Related]
15. A prospective single arm phase II study of dacarbazine and treosulfan as first-line therapy in metastatic uveal melanoma.
O'Neill PA; Butt M; Eswar CV; Gillis P; Marshall E
Melanoma Res; 2006 Jun; 16(3):245-8. PubMed ID: 16718271
[TBL] [Abstract][Full Text] [Related]
16. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
[TBL] [Abstract][Full Text] [Related]
17. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma.
Pyrhönen S; Hahka-Kemppinen M; Muhonen T; Nikkanen V; Eskelin S; Summanen P; Tarkkanen A; Kivelä T
Cancer; 2002 Dec; 95(11):2366-72. PubMed ID: 12436444
[TBL] [Abstract][Full Text] [Related]
18. Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma.
O'Day S; Gonzalez R; Lawson D; Weber R; Hutchins L; Anderson C; Haddad J; Kong S; Williams A; Jacobson E
J Clin Oncol; 2009 Nov; 27(32):5452-8. PubMed ID: 19826135
[TBL] [Abstract][Full Text] [Related]
19. A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma.
Eigentler TK; Weide B; de Braud F; Spitaleri G; Romanini A; Pflugfelder A; González-Iglesias R; Tasciotti A; Giovannoni L; Schwager K; Lovato V; Kaspar M; Trachsel E; Menssen HD; Neri D; Garbe C
Clin Cancer Res; 2011 Dec; 17(24):7732-42. PubMed ID: 22028492
[TBL] [Abstract][Full Text] [Related]
20. Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma.
McClay EF; Mastrangelo MJ; Bellet RE; Berd D
Cancer Treat Rep; 1987 May; 71(5):465-9. PubMed ID: 3567970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
